<SUBMISSION>
<ACCESSION-NUMBER>0001144204-05-014534
<TYPE>6-K
<PUBLIC-DOCUMENT-COUNT>3
<PERIOD>20050510
<FILING-DATE>20050510
<DATE-OF-FILING-DATE-CHANGE>20050510
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>pSivida LTD
<CIK>0001314102
<ASSIGNED-SIC>3826
<IRS-NUMBER>000000000
<STATE-OF-INCORPORATION>C3
<FISCAL-YEAR-END>0630
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>6-K
<ACT>34
<FILE-NUMBER>000-51122
<FILM-NUMBER>05813838
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>LEVEL 12 BGC CENTRE
<STREET2>28 THE ESPLANADE
<CITY>PERTH
<STATE>C3
<ZIP>6000
<PHONE>61 8 9226 5099
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>LEVEL 12 BGC CENTRE
<STREET2>28 THE ESPLANADE
<CITY>PERTH
<STATE>C3
<ZIP>6000
</MAIL-ADDRESS>
</FILER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v017834_6k.htm
<TEXT>
<HTML><HEAD>
<TITLE>
</TITLE>
</HEAD><BODY id=38 bgColor=#ffffff>
<DIV><BR>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><STRONG>SECURITIES
AND EXCHANGE COMMISSION</STRONG></FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>Washington,
D.C. 20549</STRONG></FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><STRONG><FONT size=2></FONT></STRONG>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><STRONG>FORM
6-K</STRONG></FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><STRONG><FONT size=5></FONT></STRONG>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">REPORT OF
FOREIGN ISSUER</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
to Rule 13a-16 or 15d-16 of</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
Securities Exchange Act of 1934</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT size=2></FONT>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>For
the month of April 2005</STRONG></FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><STRONG><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Commission
File Number 000-5112</FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2</FONT></STRONG></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT size=2></FONT>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 20pt; FONT-FAMILY: Times New Roman"><STRONG>pSivida
Limited</STRONG></FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Translation
of registrant&#8217;s name into English) </FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT size=2></FONT>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Level 12
BGC Centre</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">28 The
Esplanade</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Perth WA
6000</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Address
of principal executive offices)</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT size=2></FONT>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=left><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Indicate
by check mark whether the registrant files or will file annual reports under
cover Form&nbsp;20-F or Form&nbsp;40-F).</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=left><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"></FONT>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form 20-F
</FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#253;</FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form
40-F </FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">o</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT face=Wingdings size=2></FONT>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=left><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(1):</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=left><FONT size=2></FONT>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=left><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(7):</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=left><FONT size=2></FONT>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=left><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
by check mark whether the registrant by furnishing the information contained in
this Form is also thereby furnishing the information to the Commission pursuant
to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934.</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=left><FONT size=2></FONT>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes
</FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">o</FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
</FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#253;</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT face=Wingdings size=2></FONT>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=left><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If "Yes"
is marked, indicate below the file number assigned to the registrant in
connection with Rule&nbsp;12g3-2(b): 82- ___. </FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=left><FONT size=2></FONT>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>SIGNATURE
</STRONG></FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=left><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant,
pSivida Limited, has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized. </FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=left><FONT size=2></FONT>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=left><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date: May
10, 2005</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=left><FONT size=2></FONT>
<DIV align=center><FONT size=2></FONT>&nbsp;</DIV></DIV>
<DIV><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"></FONT>
<DIV align=center>
<TABLE cellSpacing=0 cellPadding=0 width="100%" bgColor=#ffffff>
  <TR bgColor=#ffffff>
    <TD width="47%">&nbsp;</TD>
    <TD width="53%" colSpan=2><FONT size=2>pSivida Limited</FONT></TD></TR>
  <TR bgColor=#ffffff>
    <TD width="47%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="50%">&nbsp;</TD></TR>
  <TR bgColor=#ffffff>
    <TD width="47%">&nbsp;</TD>
    <TD width="3%"><FONT
      style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">By:</FONT></TD>
    <TD width="50%"><FONT size=2>/s/ Aaron Finlay</FONT></TD></TR>
  <TR bgColor=#ffffff>
    <TD width="47%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="50%">
      <HR align=left width="45%" color=#000000 noShade SIZE=2>
    </TD></TR>
  <TR bgColor=#ffffff>
    <TD width="47%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="50%"><FONT size=2>Aaron Finlay</FONT></TD></TR>
  <TR bgColor=#ffffff>
    <TD width="47%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="50%"><EM><FONT size=2>Chief Financial Officer and Company
      Secretary</FONT></EM></TD></TR></TABLE></DIV></DIV>
<DIV>&nbsp;</DIV>
<DIV id=PGBRK style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=FTR>
<DIV id=GLFTR style="WIDTH: 100%" align=left><FONT
style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"></FONT></DIV></DIV>
<DIV id=PN style="PAGE-BREAK-AFTER: always">
<DIV style="WIDTH: 100%; TEXT-ALIGN: center"><FONT
style="DISPLAY: inline; FONT-SIZE: 8pt" face="Times New Roman"></FONT></DIV>
<DIV style="WIDTH: 100%; TEXT-ALIGN: center">
<HR color=#000000 noShade SIZE=2>
</DIV></DIV>
<DIV id=HDR>
<DIV id=GLHDR style="WIDTH: 100%" align=right><FONT
style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"></FONT></DIV></DIV></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 225pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=left><EM><FONT size=2></FONT></EM>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG><EM><U>EXHIBIT
INDEX</U></EM></STRONG></FONT></DIV>
<DIV>
<TABLE cellSpacing=0 cellPadding=0 width="100%">
  <TR>
    <TD vAlign=top align=left width="15%">
      <DIV
      style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
      align=left><FONT
      style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>EXHIBIT
      99.1:</STRONG></FONT></DIV></TD>
    <TD vAlign=top align=left width="62%">
      <DIV
      style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
      align=left><FONT
      style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Chinese
      Patent Granted</FONT><FONT
      style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman, serif"><SUP>&nbsp;</SUP></FONT></DIV></TD></TR>
  <TR>
    <TD vAlign=top align=left width="15%">&nbsp;</TD>
    <TD vAlign=top align=left width="62%">&nbsp;</TD></TR></TABLE></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=left><BR></DIV>
<DIV></DIV>
<DIV id=PGBRK style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=FTR>
<DIV id=GLFTR style="WIDTH: 100%" align=left><FONT
style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"></FONT></DIV></DIV>
<DIV id=PN>
<DIV style="WIDTH: 100%; TEXT-ALIGN: center"><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt" face="Times New Roman">-2-</FONT></DIV>
<DIV style="WIDTH: 100%; TEXT-ALIGN: center">
<HR color=#000000 noShade SIZE=2>
</DIV></DIV>
<DIV id=HDR>
<DIV id=GLHDR style="WIDTH: 100%" align=right><FONT
style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"></FONT></DIV></DIV></DIV></DIV></BODY></HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v017834_ex99-1.htm
<TEXT>
<HTML><HEAD>
<TITLE>
</TITLE>
</HEAD><BODY id=38 bgColor=#ffffff>
<DIV><BR>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=left><BR></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=right><IMG src="psivida_logo.jpg"></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=left>&nbsp;</DIV>
<DIV align=center>
<TABLE cellSpacing=0 cellPadding=0 width="100%" bgColor=#ffffff>
  <TR bgColor=#ffffff>
    <TD width="50%"><STRONG><FONT size=2>ASX/MEDIA
    RELEASE</FONT></STRONG>&nbsp;</TD>
    <TD width="50%">
      <DIV style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"
      align=right><STRONG><FONT size=2>8<FONT
      style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><SUP>th</SUP></FONT><FONT
      style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      May 2005</FONT></FONT></STRONG></DIV></TD></TR></TABLE></DIV>
<DIV>&nbsp;&nbsp;<FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>&nbsp;</STRONG></FONT>&nbsp;<FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>&nbsp;</STRONG></FONT>&nbsp;&nbsp;&nbsp;<FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>
</STRONG></FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><BR></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 24pt; FONT-FAMILY: Times New Roman"><STRONG>Chinese
Patent Granted</STRONG></FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><STRONG>Planned
Early Commercialisation of BioSilicon</STRONG></FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><SUP><STRONG>TM</STRONG></SUP></FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><STRONG>
in China</STRONG></FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><STRONG>China
is the largest global market for BrachySil</STRONG></FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><SUP><STRONG>TM</STRONG></SUP></FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><STRONG>
in liver cancer</STRONG></FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center>
<DIV>
<HR align=left width="100%" color=#000000 noShade SIZE=2>
</DIV></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><BR></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Global
nanotechnology company pSivida Limited </FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>(ASX:PSD,
NASDAQ:PSDV, Xetra:PSI)</STRONG></FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> is
pleased to announce that it has been granted its first patent in China.
</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><BR></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This
first patent grant in China is important as China has the highest incidence of
primary liver cancer in the world with 345,844 cases in 2002 and is a logical
target market for BrachySil</FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><SUP>TM</SUP></FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">. The
potential lower cost of the Chinese registration pathway and the vast need of
BrachySil</FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><SUP>TM
</SUP></FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">like
products make China an important commercial target. </FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><BR></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
is currently in exploratory discussions with commercialisation partners for the
Chinese market for its lead product BrachySil&#8482; and is investigating the optimum
regulatory process to launch this product in China. It is expected that pSivida
would enter into a supply agreement with a local distributor responsible for
obtaining regulatory approval, sales and marketing. </FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><BR></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
Managing Director Gavin Rezos said, &#8220;China is a massive market offering pSivida
significant opportunities for commercial expansion. In recent years China has
opened its &#8216;commercial doors&#8217; to many western products, healthcare being no
exception. Although our main short term interest is to launch BrachySil&#8482; in
China, we believe other products in the drug delivery arena will also be good
candidates for this rapidly growing market.&#8221;</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><BR></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Chinese
Patent Number ZL 99807447.0 provides protection for silicon implants comprising
tissue compatible biodegradable silicon for drug delivery. This invention was
based on the demonstration in model systems, that long term BioSilicon&#8482; implants
lack toxicology and degrade in the body in a controllable manner. It also claims
the loading of BioSilicon&#8482; implants of varying porosity and structure with
different drugs.</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><BR></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
pSivida Intellectual Property portfolio consists of 26 patent families, 29
granted patents and over 80 patent applications. </FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><BR></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Products
protected by patents and patent applications owned by pSivida include materials
comprising bioactive, resorbable and biocompatible silicon that are of value in
the fabrication of new generations of intelligent drug delivery devices,
orthopaedic implants and intelligent diagnostic tools.</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><BR></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><BR></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=left><BR></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>-ENDS-</STRONG></FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><BR></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG></STRONG>
<DIV align=center>
<TABLE cellSpacing=0 cellPadding=0 width="100%" bgColor=#ffffff>
  <TR bgColor=#ffffff>
    <TD width="50%">
      <DIV
      style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
      align=justify><FONT
      style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>Released
      by:</STRONG></FONT></DIV></TD>
    <TD width="50%">&nbsp;</TD></TR>
  <TR bgColor=#ffffff>
    <TD width="50%">&nbsp;</TD>
    <TD width="50%">&nbsp;</TD></TR>
  <TR bgColor=#ffffff>
    <TD width="50%"><FONT
      style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>In
      Australia:</STRONG></FONT></TD>
    <TD width="50%"><FONT
      style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>In
      US:</STRONG></FONT></TD></TR>
  <TR bgColor=#ffffff>
    <TD width="50%"><FONT
      style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Josh
      Mann, CFA</FONT></TD>
    <TD width="50%"><FONT
      style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Beverly
      Jedynak</FONT></TD></TR>
  <TR bgColor=#ffffff>
    <TD width="50%"><FONT
      style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Investor
      Relations</FONT></TD>
    <TD width="50%"><FONT
      style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">President</FONT></TD></TR>
  <TR bgColor=#ffffff>
    <TD width="50%"><FONT
      style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      Limited</FONT></TD>
    <TD width="50%"><FONT
      style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Martin
      E. Janis &amp; Company, Inc.</FONT></TD></TR>
  <TR bgColor=#ffffff>
    <TD width="50%"><FONT
      style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
      + 61 8 9226 5099</FONT></TD>
    <TD width="50%"><FONT
      style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
      312-943-1100 ext. 12</FONT></TD></TR>
  <TR bgColor=#ffffff>
    <TD width="50%"><FONT
      style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><U>joshuamann@psivida.com</U></FONT></TD>
    <TD width="50%"><FONT
      style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><U>bjedynak@janispr.com</U></FONT></TD></TR></TABLE></DIV>
<DIV align=center>&nbsp;</DIV>
<DIV style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"
align=left>&nbsp;</DIV>
<DIV id=PGBRK style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=FTR>
<DIV id=GLFTR style="WIDTH: 100%" align=left><FONT
style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"></FONT></DIV></DIV>
<DIV id=PN style="PAGE-BREAK-AFTER: always">
<DIV style="WIDTH: 100%; TEXT-ALIGN: center"><FONT
style="DISPLAY: inline; FONT-SIZE: 8pt" face="Times New Roman"></FONT></DIV>
<DIV style="WIDTH: 100%; TEXT-ALIGN: center">
<HR color=#000000 noShade SIZE=2>
</DIV></DIV>
<DIV id=HDR>
<DIV id=GLHDR style="WIDTH: 100%" align=right><FONT
style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"></FONT></DIV></DIV></DIV></FONT>
<DIV align=center>&nbsp;</DIV></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>NOTES
TO EDITORS:</STRONG></FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><BR></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=left><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>pSivida
Limited</STRONG></FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
is a global nanotechnology company committed to the biomedical sector and the
development of products in healthcare. The company&#8217;s focus is the development
and commercialisation of a modified form of silicon (porosified or
nano-structured silicon) known as BioSilicon&#8482;. As a new and exciting
biocompatible material, BioSilicon&#8482; offers multiple potential applications
across the high growth healthcare sector, including controlled release drug
delivery, targeted cancer therapies (including brachytherapy and localized
chemotherapy), tissue engineering and orthopedics. Potential diagnostics
applications are being developed through its subsidiary AION Diagnostics
Limited. </FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><BR></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
owns the intellectual property rights to BioSilicon&#8482; for use in or on humans and
animals. The IP portfolio consists of 26 patent families, 29 granted patents and
over 80 patent applications. The core patent, which recognises BioSilicon&#8482; as a
biomaterial was granted in the UK in 2000 and in the US in 2001. </FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><BR></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
is listed on NASDAQ (</FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>PSDV</STRONG></FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">), the
Australian Stock Exchange (</FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>PSD</STRONG></FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">) and in
Germany on the Frankfurt Stock Exchange on the XETRA system (</FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>German</STRONG></FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>Symbol:
PSI. Securities Code (WKN) 358705</STRONG></FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">).
pSivida&#8217;s shares also trade in the United Kingdom on the OFEX International
Market Service (IMS) under the ticker symbol </FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>PSD</STRONG></FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><BR></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
Company&#8217;s strategic partner and largest shareholder is the QinetiQ group, the
largest science and technology company in Europe. QinetiQ is the former UK
government Defence Evaluation Research Agency and was instrumental in
discovering BioSilicon&#8482;. pSivida enjoys a strong relationship with QinetiQ
having access to its cutting edge research and development facilities. For more
information on QinetiQ visit <U>www.qinetiq.com</U></FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><BR></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For more
information visit <U>www.psivida.com</U></FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><BR></DIV>
<DIV style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">This
document contains forward-looking statements that involve risks and
uncertainties. Although we believe that the expectations reflected in such
forward-looking statements are reasonable at this time, we can give no assurance
that such expectations will prove to be correct. Given these uncertainties,
readers are cautioned not to place undue reliance on such forward-looking
statements. Actual results could differ materially from those anticipated in
these forward-looking statements due to many important factors including: our
failure to develop applications for BioSilicon<SUP>TM</SUP> due to regulatory,
scientific or other issues. Other reasons are contained in cautionary statements
in the Registration Statement on Form 20-F filed with the U.S. Securities and
Exchange Commission, including, without limitation, under Item&nbsp;3.D, "Risk
Factors" therein. We do not undertake to update any oral or written
forward-looking statements that may be made by or on behalf of
pSivida.</FONT></DIV>
<DIV></DIV></DIV></BODY></HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>psivida_logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 psivida_logo.jpg
M_]C_X``02D9)1@`!`@$`2`!(``#_X0H^17AI9@``34T`*@````@`!P$2``,`
M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q
M``(````4````<@$R``(````4````AH=I``0````!````G````,@```!(````
M`0```$@````!061O8F4@4&AO=&]S:&]P(#<N,``R,#`U.C`U.C$P(#`P.C,Y
M.C$U``````.@`0`#`````?__``"@`@`$`````0```/J@`P`$`````0```$<`
M````````!@$#``,````!``8```$:``4````!```!%@$;``4````!```!'@$H
M``,````!``(```(!``0````!```!)@("``0````!```)$`````````!(````
M`0```$@````!_]C_X``02D9)1@`!`@$`2`!(``#_[0`,061O8F5?0TT``O_N
M``Y!9&]B90!D@`````'_VP"$``P("`@)"`P)"0P1"PH+$14/#`P/%1@3$Q43
M$Q@1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P!#0L+#0X-
M$`X.$!0.#@X4%`X.#@X4$0P,#`P,$1$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#/_``!$(`"0`@`,!(@`"$0$#$0'_W0`$``C_Q`$_```!
M!0$!`0$!`0`````````#``$"!`4&!P@)"@L!``$%`0$!`0$!``````````$`
M`@,$!08'"`D*"Q```00!`P($`@4'!@@%`PPS`0`"$0,$(1(Q!4%181,B<8$R
M!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5
MXF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7
MI[?'U^?W$0`"`@$"!`0#!`4&!P<&!34!``(1`R$Q$@1!46%Q(A,%,H&1%*&Q
M0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,79$55-G1EXO*S
MA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_
MV@`,`P$``A$#$0`_`/54DED]2`Q<AF10T,>"'/VB-^YT/#]OT]R@YG/[&/W#
M'BB#ZM:,8_O)B+-.LL_J/6*<*QN,RJW,SK6[JL2ANYY;.SU++';*,:G<?Y[)
MMJK_`+:S.H9>!DWW?8G%[\>TU95C=VPV[=SJF/\`YNRRC_#^G_,O_16?I%>?
M^J](:^B667MK#GR29>!N?JJYY\QS9\<L8`Y>/N3D)WQ1E'BAP1X/F3PV`0=S
M6R!^+U3(J?E=:SOV?C5M-C\7"?L:QC9>YV5U)[6Y%FUGTG8_V&O_`(SZ:+]5
MVYHZ4+,M]KVW6V6XK<@S<S&>XNQ*\A[MUCK?1][O5_2U[_1L_FU.OI.+DX]3
M;FS2U^^RJ`!8ZMWZ'U_SK65._2>F_P#PBM=3ZCC]+P+L_)#C3CMW/#!N=$AO
MM;\U<Q3,\<9$<)D!+AOBJ_%C,1$D]NK:27,N_P`87U>:['DW^ED1.1Z1%5;C
M!=5;8?\`"4[V^OZ/K>C_`(1:76,FZNRFACS2RS5]H\):.?Y$[G)G,YXX,4LL
M@2!0H=Y'ABF!$S42"ZB2SL:C/HR6EMQR,5XESGNG_,^FI6?9OVM5N=9Z^SVM
M'\W$/^DF#F3PQ,L9QDY(XN'(>'Y_T\<_5'(OX?&]+;Z2R^G?6+I_4<W-P:=]
M=_3G;;Q:W:-'/9OK,G>S]']+^HLO-Z_T3KOU6S\HNRZ>GU/;5;;4T,ND.JL_
M03O_`-)7N5FF(SC5V-B?\5ZA)86#U7I'2/JKBYWJW'`KJ:*77#=>_<=M;"UO
MTKGN_P!=BYSK/UK'4NJ]`/3+\K%99D-&3CNWTES'VX[:76-!]+(IM;ZVQ];[
M:T:1++&(!.YK3^\^@)+&ZY]:^D]$MKQ\HV6Y5H#F8U#-]A:26AT>UK=SF^SW
M^]&Z%]8NF=>I?;@.=-)`MJL;M>S=.S<W5NU^WVO8Y!=QQXN&QQ=G_]#U58K\
MK]KY^1AXE0=CX0=7?FDG;]H!;^J4M9_.^C_VIL]3]!;^B_26>M76;ZPV9YPF
MXG3BYF3F6LH=?7JZBJP_I\R!_HZFO]%W_<CTD5O[(^K_`$NNLOJP<#%:&,+W
M!K1_:?\`3ML_[<ML3,F.&2!A,<49"B$<1O32G-ZA1D44TU7"H,:7EGI`MDGW
M6.>V&MW/<[=[5;KQ,[*HQFV/J;CL:US6C<7$;?8Y_P!'W?VE1S<S+ZP*WX>-
M=1AMDMR;:CZM@/\`W%Q'C]$W3^D9[&?\%AY2V.EMK9C-8UEC'M:WU#:';BZ/
M]);_`#BRX<G$\[FCDG(PG&'#'C/'DX(Q_G)?]SQ<;)Q^D4-NO_>MJNMM;&L;
MHUH@+%^NO_B6ZC_Q0_ZIBW%C?6^B_(^K6?3CUONM?6`RNMI<YQW-^BQON<M>
M(`H#0#1BR:PEY%XKK9'_`(V?2>)];3Y#+E=Y?=A^CCXV:TEUC6D.(C:8V[O4
M_-_E+G?J_P#4?I.5TSI^7U+%MKRV-+K\=Y>QKG!QAV1C._.<UC-_T/6_PWJ+
MKLG$HRF!ES=T?1/!'P<HN:C.>*4<?`9'IE'%CD/THR6<O$@\4M+C$:?U0Y58
M?T[J->-58;*;2)8>V[3_`#OSD>[_`)>H_P"+_A:K.+TS$Q7^I6TEXX<XR1/[
MJ([$I=E-RB#ZK!M!G2/</H_VU1Q\EF&.,3PQ`YB&:.+BE..'%C/%*$9R;!D+
M^E6\#];+G="^LN=EL!#.K].LK#@(`MAM.[_K?I4V._XU7<GI_P"SO\6#J2-M
MCZJ[K!$'=;;7=M=_Q;7^G_872=;^KG2NNBD=18Y_V<N->Q[F:/V^HUVP^YKM
MC%:ZETW%ZG@6=/R@3CW`![6$M,-+7MVN;]'W,6I>S5.$WDV]0(A_A_,\#]89
M_P#&TZ3'[U7_`%%RN_6PUGJ7U2],M+/586;8C:;,+;MC\U=39]7NEV]&;T2R
MLOPF-:QC2X[QM.ZM[;?I[V.5#'^H?U>QSC/978;<2P7,N=8XO+FEKZVV._T5
M>SV4M_1?YZ5H.&6PK40'_A;2ZIU!]WUI/3>A8&(>L55A^3U3)8":F%K?;7LV
MW6N].ZK_``G^%]/_`$OIT_J"VQOU@Z^VVT7V-L`LO`#18X6Y.^UK&[FL]1WO
MV+>ZI]3>A]5Z@.H9++!>0!::K'5BP`;!ZGID._F_T?Z/T_T:L=(^K?2>C9&1
M?T^MU1R8#V;B6`-+G,;56?;6UN_\U*]%WMS.02-4)$_0C]U__]'K_K7]B^VX
MD?M+]H^G9L_9/\YZ,L]7[3O_`$/H>KZ6S?\`X7^;0^B_\TOM]7J>K^VH'I_M
M?U?M<]OL_P!O]F[_`,(+Y_21Z,/^4_1^O\OF?JI)?*J2#,_522^54DE/U4DO
ME5))3]5)+Y5224_522^54DE/U4DOE5))3]5)+Y5224__V?_M#OA0:&]T;W-H
M;W`@,RXP`#A"24T$)0``````$``````````````````````X0DE-`^T`````
M`!``2`````$``0!(`````0`!.$))300F```````.`````````````#^````X
M0DE-!`T```````0```!X.$))3009```````$````'CA"24T#\P``````"0``
M`````````0`X0DE-!`H```````$``#A"24TG$```````"@`!``````````$X
M0DE-`_4``````$@`+V9F``$`;&9F``8```````$`+V9F``$`H9F:``8`````
M``$`,@````$`6@````8```````$`-0````$`+0````8```````$X0DE-`_@`
M`````'```/____________________________\#Z`````#_____________
M________________`^@`````_____________________________P/H````
M`/____________________________\#Z```.$))300````````"``$X0DE-
M!`(```````0`````.$))300(```````0`````0```D````)``````#A"24T$
M'@``````!``````X0DE-!!H``````TD````&``````````````!'````^@``
M``H`50!N`'0`:0!T`&P`90!D`"T`,0````$`````````````````````````
M`0``````````````^@```$<``````````````````````0``````````````
M```````````0`````0```````&YU;&P````"````!F)O=6YD<T]B:F,````!
M````````4F-T,0````0`````5&]P(&QO;F<``````````$QE9G1L;VYG````
M``````!"=&]M;&]N9P```$<`````4F=H=&QO;F<```#Z````!G-L:6-E<U9L
M3',````!3V)J8P````$```````5S;&EC90```!(````'<VQI8V5)1&QO;F<`
M````````!V=R;W5P241L;VYG``````````9O<FEG:6YE;G5M````#$53;&EC
M94]R:6=I;@````UA=71O1V5N97)A=&5D`````%1Y<&5E;G5M````"D53;&EC
M951Y<&4`````26UG(`````9B;W5N9'-/8FIC`````0```````%)C=#$````$
M`````%1O<"!L;VYG``````````!,969T;&]N9P``````````0G1O;6QO;F<`
M``!'`````%)G:'1L;VYG````^@````-U<FQ415A4`````0```````&YU;&Q4
M15A4`````0```````$US9V5415A4`````0``````!F%L=%1A9U1%6%0````!
M```````.8V5L;%1E>'1)<TA434QB;V]L`0````AC96QL5&5X=%1%6%0````!
M```````):&]R>D%L:6=N96YU;0````]%4VQI8V5(;W)Z06QI9VX````'9&5F
M875L=`````EV97)T06QI9VYE;G5M````#T53;&EC959E<G1!;&EG;@````=D
M969A=6QT````"V)G0V]L;W)4>7!E96YU;0```!%%4VQI8V5"1T-O;&]R5'EP
M90````!.;VYE````"71O<$]U='-E=&QO;F<`````````"FQE9G1/=71S971L
M;VYG``````````QB;W1T;VU/=71S971L;VYG``````````MR:6=H=$]U='-E
M=&QO;F<``````#A"24T$$0```````0$`.$))3004```````$`````CA"24T$
M#``````)+`````$```"`````)````8```#8````)$``8``'_V/_@`!!*1DE&
M``$"`0!(`$@``/_M``Q!9&]B95]#30`"_^X`#D%D;V)E`&2``````?_;`(0`
M#`@("`D(#`D)#!$+"@L1%0\,#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,
M#`P1$0P,#`P,#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`
M)`"``P$B``(1`0,1`?_=``0`"/_$`3\```$%`0$!`0$!``````````,``0($
M!08'"`D*"P$``04!`0$!`0$``````````0`"`P0%!@<("0H+$``!!`$#`@0"
M!0<&"`4###,!``(1`P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,'
M)9)3\.'Q8W,U%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34
MY/2EM<75Y?569G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'
M!P8%-0$``A$#(3$2!$%187$B$P4R@9$4H;%"(\%2T?`S)&+A<H*20U,58W,T
M\24&%J*R@P<F-<+21)-4HQ=D154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%
MU>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:``P#`0`"$0,1`#\`]52263U(
M#%R&9%#0QX(<_:(W[G0\/V_3W*#F<_L8_<,>*(/JUHQC^\F(LTZRS^H]8IPK
M&XS*K<S.M;NJQ*&[GEL[/4LL=LHQJ=Q_GLFVJO\`MK,ZAEX&3?=]B<7OQ[35
ME6-W;#;MW.J8_P#F[+*/\/Z?\R_]%9^D5Y_ZKTAKZ)99>VL.?))EX&Y^JKGG
MS'-GQRQ@#EX^Y.0G?%&4>*'!'@^9/#8!!W-;('XO5,BI^5UK._9^-6TV/Q<)
M^QK&-E[G974GM;D6;6?2=C_8:_\`C/IHOU7;FCI0LRWVO;=;9;BMR#-S,9[B
M[$KR'NW6.M]'WN]7]+7O]&S^;4Z^DXN3CU-N;-+7[[*H`%CJW?H?7_.M94[]
M)Z;_`/"*UU/J./TO`NS\D.-..W<\,&YT2&^UOS5S%,SQQD1PF0$N&^*K\6,Q
M$23VZMI)<R[_`!A?5YKL>3?Z61$Y'I$55N,%U5MA_P`)3O;Z_H^MZ/\`A%I=
M8R;J[*:&/-++-7VCPEHY_D3N<F<SGC@Q2RR!(%"AWD>&*8$3-1(+J)+.QJ,^
MC):6W'(Q7B7.>Z?\SZ:E9]F_:U6YUGK[/:T?S<0_Z28.9/#$RQG&3DCBX<AX
M?G_3QS]4<B_A\;TMOI++Z=]8NG]1S<W!IWUW].=MO%K=HT<]F^LR=[/T?TOZ
MBR\WK_1.N_5;/RB[+IZ?4]M5MM30RZ0ZJS]!._\`TE>Y6:8C.-78V)_Q7J$E
MA8/5>D=(^JN+G>K<<"NIHI=<-U[]QVUL+6_2N>[_`%V+G.L_6L=2ZKT`],OR
ML5EF0T9..[?27,?;CMI=8T'TLBFUOK;'UOMK1I$LL8@$[FM/[SZ`DL;KGUKZ
M3T2VO'RC9;E6@.9C4,WV%I):'1[6MW.;[/?[T;H7UBZ9UZE]N`YTTD"VJQNU
M[-T[-S=6[7[?:]CD%W''BX;'%V?_T/55BOROVOGY&'B5!V/A!U=^:2=OV@%O
MZI2UG\[Z/_:FSU/T%OZ+])9ZU=9OK#9GG";B=.+F9.9:RAU]>KJ*K#^GS('^
MCJ:_T7?]R/216_LCZO\`2ZZR^K!P,5H8PO<&M']I_P!.VS_MRVQ,R8X9(&$Q
MQ1D*(1Q&]-*<WJ%&11335<*@QI>6>D"V2?=8Y[8:W<]SMWM5NO$SLJC&;8^I
MN.QK7-:-Q<1M]CG_`$?=_:5'-S,OK`K?AXUU&&V2W)MJ/JV`_P#<7$>/T3=/
MZ1GL9_P6'E+8Z6VMF,UC66,>UK?4-H=N+H_TEO\`.++AR<3SN:.2<C"<8<,>
M,\>3@C'^<E_W/%QLG'Z10VZ_]ZVJZVUL:QNC6B`L7ZZ_^);J/_%#_JF+<6-]
M;Z+\CZM9]./6^ZU]8#*ZVESG'<WZ+&^YRUX@"@-`-&+)K"7D7BNMD?\`C9])
MXGUM/D,N5WE]V'Z./C9K276-:0XB-IC;N]3\W^4N=^K_`-1^DY73.GY?4L6V
MO+8TNOQWE[&N<'&'9&,[\YS6,W_0];_#>HNNR<2C*8&7-W1]$\$?!RBYJ,YX
MI1Q\!D>F4<6.0_2C)9R\2#Q2TN,1I_5#E5A_3NHUXU5ALIM(EA[;M/\`._.1
M[O\`EZC_`(O^%JLXO3,3%?ZE;27CASC)$_NHCL2EV4W*(/JL&T&=(]P^C_;5
M''R688XQ/#$#F(9HXN*4XX<6,\4H1G)L&0OZ5;P/ULN=T+ZRYV6P$,ZOTZRL
M.`@"V&T[O^M^E38[_C5=R>G_`+._Q8.I(VV/JKNL$0=UMM=VUW_%M?Z?]A=)
MUOZN=*ZZ*1U%CG_9RXU['N9H_;ZC7;#[FNV,5KJ73<7J>!9T_*!./<`'M82T
MPTM>W:YOT?<Q:E[-4X3>3;U`B'^'\SP/UAG_`,;3I,?O5?\`47*[];#6>I?5
M+TRTL]5A9MB-ILPMNV/S5U-GU>Z7;T9O1+*R_"8UK&-+CO&T[JWMM^GO8Y4,
M?ZA_5['.,]E=AMQ+!<RYUCB\N:6OK;8[_15[/92W]%_GI6@X9;"M1`?^%M+J
MG4'W?6D]-Z%@8AZQ56'Y/5,E@)J86M]M>S;=:[T[JO\`"?X7T_\`2^G3^H+;
M&_6#K[;;1?8VP"R\`-%CA;D[[6L;N:SU'>_8M[JGU-Z'U7J`ZADLL%Y`%IJL
M=6+`!L'J>F0[^;_1_H_3_1JQTCZM])Z-D9%_3ZW5')@/9N)8`TN<QM59]M;6
M[_S4KT7>W,Y!(U0D3]"/W7__T>O^M?V+[;B1^TOVCZ=FS]D_SGHRSU?M._\`
M0^AZOI;-_P#A?YM#Z+_S2^WU>IZO[:@>G^U_5^USV^S_`&_V;O\`P@OG])'H
MP_Y3]'Z_R^9^JDE\JI(,S]5)+Y5224_522^54DE/U4DOE5))3]5)+Y5224_5
M22^54DE/U4DOE5))3__9.$))300A``````!5`````0$````/`$$`9`!O`&(`
M90`@`%``:`!O`'0`;P!S`&@`;P!P````$P!!`&0`;P!B`&4`(`!0`&@`;P!T
M`&\`<P!H`&\`<``@`#<`+@`P`````0`X0DE-!`8```````<``0````$!`/_A
M$DAH='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O`#P_>'!A8VME="!B96=I
M;CTG[[N_)R!I9#TG5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED)S\^"CP_861O
M8F4M>&%P+69I;'1E<G,@97-C/2)#4B(_/@H\>#IX87!M971A('AM;&YS.G@]
M)V%D;V)E.FYS.FUE=&$O)R!X.GAA<'1K/2=835`@=&]O;&MI="`R+C@N,BTS
M,RP@9G)A;65W;W)K(#$N-2<^"CQR9&8Z4D1&('AM;&YS.G)D9CTG:'1T<#HO
M+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R<@>&UL;G,Z
M:5@])VAT='`Z+R]N<RYA9&]B92YC;VTO:5@O,2XP+R<^"@H@/')D9CI$97-C
M<FEP=&EO;B!A8F]U=#TG=75I9#ID9&(Y8V%A92UC,3!C+3$Q9#DM8C<R-RUC
M-&4Q-6(Y-S,V-SDG"B`@>&UL;G,Z>&%P34T])VAT='`Z+R]N<RYA9&]B92YC
M;VTO>&%P+S$N,"]M;2\G/@H@(#QX87!-33I$;V-U;65N=$E$/F%D;V)E.F1O
M8VED.G!H;W1O<VAO<#ID9&(Y8V%A8RUC,3!C+3$Q9#DM8C<R-RUC-&4Q-6(Y
M-S,V-SD\+WAA<$U-.D1O8W5M96YT240^"B`\+W)D9CI$97-C<FEP=&EO;CX*
M"CPO<F1F.E)$1CX*/"]X.GAA<&UE=&$^"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H\/WAP86-K970@96YD/2=W)S\^
M_^X`#D%D;V)E`&2``````?_;`(0`#`@("`D(#`D)#!$+"@L1%0\,#`\5&!,3
M%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`$-"PL-
M#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,#!$,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,_\``$0@`1P#Z`P$B``(1`0,1`?_=``0`$/_$`3\`
M``$%`0$!`0$!``````````,``0($!08'"`D*"P$``04!`0$!`0$`````````
M`0`"`P0%!@<("0H+$``!!`$#`@0"!0<&"`4###,!``(1`P0A$C$%05%A$R)Q
M@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D1<*C=#87
MTE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]C='5V=W
MAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$#(3$2!$%187$B$P4R@9$4
MH;%"(\%2T?`S)&+A<H*20U,58W,T\24&%J*R@P<F-<+21)-4HQ=D154V=&7B
M\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>W
MQ__:``P#`0`"$0,1`#\`]522224I)1-C`=I<`?"=5)`$'8J4DDDBI28D`2=`
M%3ZKU-O3<?U?0NRGG1E6/6Y[B?/:-K/[:POV9]8?K%[^KV'IG3CJ,"@_I7M_
M[LW?]\1I9*=&@#*7;_OI-S.^MV%7D'"Z94_JF<.:L?5C3_PU_P#-L035]>LM
MIL];#Z=^[2&FYW]NP^W_`#%L=.Z?TWIE(Q<&NNA@_-;&XGQ>[Z;W*E]9NK6X
M6(W%PF^KU/.)IQ*AS)^G<?W:Z6^[<@"#MJMD)493D?[L/3_Z$A^I_7,SK&!<
M[-8T9&-::7V,$-?'YS0M]9OU?Z.SHW2J<)IWO;[KG_O6.UL<M)([KL8D(1XM
M95JI))))>I))))2DDDDE*22224I))))2DDDDE*22224I))))2DDDDE*22224
M_P#_T/54DDDE.?U'#Q=KLAS6[R0"Y[BT>'YJJ]*S'UY'V2QXL8[1C@9`//M/
M[JT\S=]G=MW2(^B0#S_+]JQ3N'4:''=)<WZ9:3S_`,'[5B\]_1^:Q9L0X+E'
MW.&/#')')+]9QS_29(ZQ(+IYO3V7%]_J/8[;P#IH/!8'JV?ON^\JS_SARNI]
M8.#TJK?@8A<.H9;A[9#7#T*9_.WJIV57X]CCBR8I0'"<G'*='YCZ58)B8-:@
M&O\`>=_`Z>UC:L@VO<\MW03[=1X('5\Q_JC$J?L!CU'<<]I6CA_T6G^HW\BQ
MK9=U:TC<2"?HEH.@_P"$]JM\X!AY/#CPW#[Q*$9\-F52CZ_\94=9$GHV</'Q
M:ZOM08++*C#/2<7%SH_E1[G*?3NEO9E6=4SB+.H7#8(U;35^;C4?^C;/\+8K
M>#N]"7;I)/TRTG_P/VJPM'D\<<>"`C$1XAQ2J/!9_K18YBY6=:V4DDN#^N/U
MLZWTKK3L/"M8RD5,>`Y@<9=NW>XJR!;'ERQQQXI75UH]XDO/.H_6KZVY>(<W
MIN,_&Z=4T;LG8"YT#WV^_P"C7N_T;%?^I/UPS.J93NG=2+7W;2^BYHVDAOTV
M6-;[?Y27":M8.9QF8AJ.+Y21Z9/69V6W$H-A&YQ,,;XE8O[0ZG>X^FYQ_DL'
M"N]>8XU5/'T6N(=\^$'H^;10'4V^PO,AYX_JN6!SV;)DY\<M+/+EL(`J43P<
M<C'B^;_FMR(`C=64>/U?+ILVY'Z1H,.!$."W6/;8QKV&6N$@^157(Z;C9=HN
M<3Q!VG0JS32RFMM58AC=`.5?Y##S>&62&;)[N'_)3D;R?^BK9&)JA1ZN3GX7
M4+<I[Z0[TS$0Z.WQ6NP$,:#R`)6/U#J>71EOJK<`QL0")Y"-U[(S\?H>1E8#
M@W*IK]5I+0X$-]U@VG^0F\@<!YCFAB.0SX_UON5P"7%/^;1D)$`3L!>F[J)+
MBOJ1];.H]6S[\3J-C'GT_4IVM#=6F+![?ZR)]>?K3U#H^3C8O3GM98]CK+BY
MH=I.VOZ7]M:7";IK_>(>W[NO#^+U]@)K<!R087GWU?\`J[]:\7KF+D9@L^RU
MV$V3=N$0[\S>=RZSZMYG4,OH%.;GN#LFYKK)#0T!LGT_:/Y*Y'ZO?7/K^=UW
M%PLFUCJ+;"UX%8!(`<?I?V41>JS++&3B,N(<1N%?]T^BI*EUCJ=72NFWY]HW
M"ELAO[SC[6,_M.7GF'];OKIU/.(P"+7@%YQV5M+`W^47>[_P1`1)9,N>&,B)
MLREL(BV_]=_K+UOIG6SC8.2::?18_9M:=3ND^YI\%V?0\B[)Z/AY%[M]MM+'
MO=Q)(U.B\H^M/4LKJ/4S=F8QQ,EE3:KJ73])N[W-W?FNW+U+ZN$#ZOX!)@#'
M823_`%49#0,'+Y#+-EU)CT!=-)><]9_Q@]4R,UV+T1H94';*W[?4LL,QN8WZ
M+=WYGM51WUO^N72KVMSYD^[TLBH-W#^2YH8Y+A*\\YB!/S$#0R`]+ZBDJ'0^
MKT]9Z93GU#9Z@(>PZEKVZ/8KZ:S\4>'BOTUQ7X/_T?54DDDE([Q6:7^K`KVD
MN+OH@#NZ5SUSL=]=>1CVUN:?=592R&.^%C26[FJEU3,ROK5U)_0^F/-?3,<_
MY1S&_G0?YBLKJ<3I^'A8E>%CU-9CU"&LB1\7?O.<JG/<C'F858C,?+(V?^C*
M",64F1H>@:7^]+^JT,7J6!7C/J%8H>_<YX:WVN>[5S_;^^Y9'9=)?T_"-;W>
MBT$-)!&G;R7-]E@?&(\S$X1S$X9"!+@E`$2/RW[C8Q\.O"*=IG6,:G%8QDOL
M:P"(@2!XJEAU_:+BZ0^VPDD.K+VB?SB?HM6GC86`**7/K;O>T<ZR8\%=8QC!
MM8T-'@!"TX<CS&?V9\QDA[>.(X,>,3ZCOZ?6LX@+H&UJ:FU5-K:``T?FB!/?
M13226M$"(`&@`H,:EY5_C&_\4C_^(K_[\O55Y5_C&_\`%(__`(BO_OR?#=J\
M]_,_X0>^Z4T.^J^.UPEKL,`@^&Q><_49Q;]:,.-)]0'X>F]=]TSJ.#7]4:L@
MWL-=.(`\@C1P9M+/Z^Y<%]0ZW6?6C$(_,%CS\`QP_P"_(C:3'FUGRU>'_<OK
M3V,L86/`<UVA!6/E]$>V7XIW#_1NY_LN5GJV5EXP8ZD@5NT)B2"H],ZFQ]9K
MR;`+03#G:2%C\W/DN8S_`'7/$QR1'IRGT?XDW1CQ`<0^QS<;-R<*S;KM!]]3
MO]?:NAIN9=4VUGT7B0L+K%]%V2#20[:V'.'!*U.D-<W`9N[DD?`E0?"LD\?-
M9N5&3WL.,$PEOPT1M_C+L@!B)51<CJW]/M^7Y`N@#&V8XK>):]FUP\01!7/]
M6_I]OR_(%T-7\TS^J/R)_P`*_P!V<]_M/^[R(R?+'R?)NA/?T/ZX546:"N]V
M,^>[7GTVG_J'*?ULMLZM];;<>KW$6,Q*P/+V._\`!'/5G_&#ANPOK$S-KT&2
MUMK3X/K.T_\`4L0_J-C6=2^M`S+O<:`_)L=XO=[6_P#3>MW^MX..0>+[OT]R
M_P#!?364,Q\(45Z,JKV-^#6[5Y+]4?\`Q4X/_&N_ZEZ]>M_FG_U3^1>0_5'_
M`,5.#_QKO^I>A'8MCF_YS!_>_P"]>\_QADCZLW1WLK!_SEC_`.*UC8ZC9'NF
MML^4/<MG_&$PN^K%Y'YKZW'X;@L'_%AET5VYV*]P;98&6,!,2&[FOC^KN0'R
ME4_]V0O]W_OG-_QC_P#BC/\`X7K_`"O7H'U?K9;]7,*MXEC\9C7#Q!;!7G?^
M,'(HO^L3S38VP,I8QQ:9`<-VYNGQ7<8^=9T_ZDU9M8FRC#:Y@/[VWVHG8(P$
M>_G/35JY5?U)^JV0S)-3*LQ@/IUL+GV0X;9]/<=OM_.>N1^MWUIK^L`H%.,Z
MFK'<XML>9<XN`]OM]K>/WT/ZJ8.+USKQ'5K2\%KKGA[H-KY'L+OGN6Q_C&MZ
M:RG!Z?A&MKJ'/<^FH`!C2`UN[9[6[D@*(ZECG.4\,Y#AQX^D1\TW8_Q:_P#B
M>=_X8L_(U=8N3_Q:_P#B>=_X8L_(U=8A^DS_`/@3_`?_TO55S/UQZME-%'0N
MF'_*'4CLW`P65'1[_P"3N_ZC>NBR+Z\>BR^PQ74TO<?)HW%8^-TAS_K*_KSB
MVVB[%8S',R6'\^/Y+V?GHACR61PQ_2-'PAU;G1.CXO1NG5X6./HB;+.[WGZ=
MCEH*%MM5+#9:]M;!RYQ``^97.YWUXP6W?9.CU/ZKFG0,I!V`_P`NW_R*6I29
M0Q@`D`=!_8]#>0*+"X@`-,DZ#A<77E69A<WIX#ZV:6YKY%#/Y+'#W9-O_!5*
M^SH/6^K`9'UAN#F<U]*I<64C_P`,V-]UW]177](SGAK/T;*V"*ZF>UC1^ZQ@
M:LGXK@$Y0D,,^8G`'AA'3#ZOTLL_TO[D%^.4C_JXGO\`SG_H+?Z;AUTT,M+W
M7VN8)NLC='[K6-]E3/Y#%=5##JZG465VNK-+1!CZ4`:*^K_+Y#/&#*$L9`$3
M&8X.GZ(_=20!LI)))3(4O*O\8W_BD?\`\17_`-^7JJXGZV_4SJO6>KNS<5]+
M:C6Q@%CG`RW=/T6.\4Z)HM?FX2GBJ(LV&HW_`!>U=0Z;B9F!D?9K+Z6/NJLE
MS"XM]SVQ[FK>^JWU/HZ"Y^19;]HS+!LW@;6M;SMK'\K\Y;'2L6S#Z;BXMI!L
MHJ96\MXEHVF%;0,CLNQ\OCB1/AJ5,+:J[JS78-S'<A95O0#N_16^WP</[EL)
M*KS/)<OS->[#B(VE\LO\:+.)$;%RL?H5;7!U[_4`_-`@'XK4````$`:`)TD[
ME^4P<O$QPP$+W.\I><I*,B=W,R^CG)R'W>KMW1I$\"%HL;M:&^``^Y221Q<K
MAQ3R9,<>&64\60V3Q%1D2`#T<+ZU?5AGU@HH8+OL]F.XN:_;NEKA#F<M\&J'
MU5^JK/J^,@F[[1;D%OOV[8:W\WEWYSET"2GLU3'[4./W*]?=B]NYCF\2"/O7
M']'_`,7S^F]5HZ@<T6"AY?Z?IQ,APC=N_E+LDD@2%3QPF8F0LQUBAS,2C-Q;
M<3(;OIN:6/;Y%<([_%?>,G]%U`#'G0EA]0#^R[9N7H*20)",F''DHR%UL\3G
M_P"+3%M;0S"R?L[:F%MCG-WNL>3N-KW;F_YJZC&Z757T>OI60?6J;2*+#$;A
M&P_U5>22LJCAQQ),8UQ"B^?7?XK\@7G[-GM%,^W>P[P/[!VJW=_BRQ#B5UT9
M3FY(>779#V[MP(C8VL.&Q=LDEQ%8.5PZ^G=R/JQT)W0NGNPG7"^;'6!X;M^E
M'MB7?NK7222O6V3VX\'!7IJJ?__3].S:Z;<.^K(<&4OK<VQY(`#2"'.W'Z/M
M7&87U:^M=%(KZ1URM_3S_,.!+AL_D^VUG_;;UX>DB+8<W!8XN+BZ<'%Q5_@O
MNMOU4P6O;;]9^MNR'?Z.RT5,_P#!';ETG1JN@U4&OHIQS4/I''<U^O\`+>PO
M=_G+YF22-]58O9OT5Q=;^?\`YWJ?JI)?*J2#,_522^54DE/U4DOE5))3]5)+
MY5224_522^54DE/U4DOE5))3]5)+Y5224_522^54DE/U4DOE5))3]5)+Y522
?4_522^54DE/U4DOE5))3]5)+Y5224_522^54DE/_V3\_
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
